206 related articles for article (PubMed ID: 15897570)
1. The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer.
Goodheart MJ; Ritchie JM; Rose SL; Fruehauf JP; De Young BR; Buller RE
Clin Cancer Res; 2005 May; 11(10):3733-42. PubMed ID: 15897570
[TBL] [Abstract][Full Text] [Related]
2. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
Laframboise S; Chapman W; McLaughlin J; Andrulis IL
Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
4. Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients.
Alvarez AA; Axelrod JR; Whitaker RS; Isner PD; Bentley RC; Dodge RK; Rodriguez GC
Gynecol Oncol; 2001 Aug; 82(2):273-8. PubMed ID: 11531279
[TBL] [Abstract][Full Text] [Related]
5. [Prognostic value of microvessel density and angiogenesis-related molecules in epithelial ovarian cancer].
Tan XJ; Lang JH; Lou WZ; Shen K; Xu XY
Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):274-8. PubMed ID: 18788631
[TBL] [Abstract][Full Text] [Related]
6. Distant metastases in ovarian cancer: association with p53 mutations.
Sood AK; Sorosky JI; Dolan M; Anderson B; Buller RE
Clin Cancer Res; 1999 Sep; 5(9):2485-90. PubMed ID: 10499623
[TBL] [Abstract][Full Text] [Related]
7. Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study.
Secord AA; Darcy KM; Hutson A; Lee PS; Havrilesky LJ; Grace LA; Berchuck A;
Gynecol Oncol; 2007 Jul; 106(1):221-32. PubMed ID: 17481705
[TBL] [Abstract][Full Text] [Related]
8. The prognostic significance of angiogenesis in epithelial ovarian carcinoma.
Alvarez AA; Krigman HR; Whitaker RS; Dodge RK; Rodriguez GC
Clin Cancer Res; 1999 Mar; 5(3):587-91. PubMed ID: 10100710
[TBL] [Abstract][Full Text] [Related]
9. p21 expression predicts outcome in p53-null ovarian carcinoma.
Rose SL; Goodheart MJ; DeYoung BR; Smith BJ; Buller RE
Clin Cancer Res; 2003 Mar; 9(3):1028-32. PubMed ID: 12631602
[TBL] [Abstract][Full Text] [Related]
10. p53 and bcl-2 in epithelial ovarian carcinoma: their value as prognostic indicators at a median follow-up of 60 months.
Geisler JP; Geisler HE; Miller GA; Wiemann MC; Zhou Z; Crabtree W
Gynecol Oncol; 2000 May; 77(2):278-82. PubMed ID: 10785478
[TBL] [Abstract][Full Text] [Related]
11. Cathepsin D in ovarian cancer: prognostic value and correlation with p53 expression and microvessel density.
Lösch A; Schindl M; Kohlberger P; Lahodny J; Breitenecker G; Horvat R; Birner P
Gynecol Oncol; 2004 Feb; 92(2):545-52. PubMed ID: 14766246
[TBL] [Abstract][Full Text] [Related]
12. The effect of cyclooxygenase-2 expression on tumor vascularity in advanced stage ovarian serous carcinoma.
Ali-Fehmi R; Che M; Khalifeh I; Malone JM; Morris R; Lawrence WD; Munkarah AR
Cancer; 2003 Oct; 98(7):1423-9. PubMed ID: 14508829
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
Chan JK; Tian C; Monk BJ; Herzog T; Kapp DS; Bell J; Young RC;
Cancer; 2008 May; 112(10):2202-10. PubMed ID: 18348296
[TBL] [Abstract][Full Text] [Related]
14. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer.
Reles A; Wen WH; Schmider A; Gee C; Runnebaum IB; Kilian U; Jones LA; El-Naggar A; Minguillon C; Schönborn I; Reich O; Kreienberg R; Lichtenegger W; Press MF
Clin Cancer Res; 2001 Oct; 7(10):2984-97. PubMed ID: 11595686
[TBL] [Abstract][Full Text] [Related]
15. P53 mutation does not affect prognosis in ovarian epithelial malignancies.
Fallows S; Price J; Atkinson RJ; Johnston PG; Hickey I; Russell SE
J Pathol; 2001 May; 194(1):68-75. PubMed ID: 11329143
[TBL] [Abstract][Full Text] [Related]
16. The expression of thrombospondin-1 and p53 in clear cell renal cell carcinoma: its relationship to angiogenesis, cell proliferation and cancer specific survival.
Zubac DP; Bostad L; Kihl B; Seidal T; Wentzel-Larsen T; Haukaas SA
J Urol; 2009 Nov; 182(5):2144-9. PubMed ID: 19758660
[TBL] [Abstract][Full Text] [Related]
17. Determination of molecular marker expression can predict clinical outcome in colon carcinomas.
Galizia G; Lieto E; Ferraraccio F; Orditura M; De Vita F; Castellano P; Imperatore V; Romano C; Ciardiello F; Agostini B; Pignatelli C
Clin Cancer Res; 2004 May; 10(10):3490-9. PubMed ID: 15161706
[TBL] [Abstract][Full Text] [Related]
18. COX-2 status in relation to tumor microvessel density and VEGF expression: analysis in ovarian carcinoma patients with low versus high survival rates.
Raspollini MR; Amunni G; Villanucci A; Boddi V; Baroni G; Taddei A; Taddei GL
Oncol Rep; 2004 Feb; 11(2):309-13. PubMed ID: 14719060
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Havrilesky L; Darcy kM; Hamdan H; Priore RL; Leon J; Bell J; Berchuck A;
J Clin Oncol; 2003 Oct; 21(20):3814-25. PubMed ID: 14551300
[TBL] [Abstract][Full Text] [Related]
20. Mutation and overexpression of p53 in early-stage epithelial ovarian cancer.
Kohler MF; Kerns BJ; Humphrey PA; Marks JR; Bast RC; Berchuck A
Obstet Gynecol; 1993 May; 81(5 ( Pt 1)):643-50. PubMed ID: 8469448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
